Unlocking the potential of liquid biopsy for molecular diagnostics. Expanding the range of biomarkers that can be detected to enable diagnosis, patient stratification and disease monitoring.
XPOTDx is developing a QCMD biosensing platform designed to broaden the range of molecular biomarkers that can be detected from minimally invasive samples, opening new opportunities for diagnosis, patient stratification and disease monitoring.
XPOTDx at a Glance
XPOTDx is a Valencia-based molecular diagnostics company developing proprietary sensing technologies for clinical applications. Founded around HFF-QCMD sensor technology, the company is currently advancing multiple diagnostic programmes and building the foundation for a scalable molecular diagnostics platform.
🔬 THE SCIENCE
DNA diagnostics
Building on technology and validation generated through two previous European projects with AWSensors, XPOTDx is applying HFF-QCMD sensor arrays to molecular diagnostics and liquid biopsy applications.
Established technology foundation
Technology and detection capabilities demonstrated through two previous European projects with AWSensors.
DNA biomarkers
Previous work demonstrated the detection of clinically relevant DNA targets, including:
KRAS G12D · BRAF V600E · BRCA1
0.01% MAF
Sensitivity demonstrated in previous project work.
XPOTDx is now building on this technology foundation to develop its own diagnostic applications.
Liquid biopsy
The full potential of liquid biopsy has yet to be unlocked. While liquid samples offer a minimally invasive window into molecular information, many clinically relevant biomarkers remain challenging to detect and translate into diagnostic applications. XPOTDx aims to unlock this potential through its next-generation sensing platform.
Minimally invasive
Accessing molecular information through liquid samples could reduce reliance on invasive tissue sampling.
Broader biomarker detection
Expanding the range of clinically relevant biomarkers that can be detected from liquid biopsy.
Clinical utility
Enabling new opportunities in diagnosis, patient stratification and disease monitoring.
Multi-biomarker potential
Molecular diagnostics are increasingly moving beyond single biomarkers. XPOTDx is developing a sensing platform with the potential to detect different classes of clinically relevant biomarkers from liquid biopsy, creating opportunities to extract richer molecular information from a single minimally invasive sample.
Different Biomarker Classes
Our platform is being developed with the potential to address multiple molecular biomarker classes, including DNA, RNA and miRNAs.
Beyond Single Biomarkers
The potential to combine multiple biomarkers to generate richer molecular profiles and support applications such as diagnosis, patient stratification and disease monitoring.
Strategic Technology Partnerships
XPOTDx is partnering with Destina Genomics to combine complementary technologies and accelerate the development of next-generation molecular detection capabilities.
💼 THE OPPORTUNITY
Platform with multiple clinical applications
Beyond diagnostic applications, XPOTDx’s platform can support the validation and development of emerging biomarkers, helping translate promising discoveries into clinically relevant applications. Its versatile sensing approach is designed to address a broad range of clinical needs, from biomarker validation, early diagnosis and disease classification to patient stratification and disease monitoring.
A new approach to molecular diagnostics
Liquid biopsy has the potential to transform how molecular information is obtained from patients, but its clinical potential remains limited by the technologies available to detect and interpret low-abundance biomarkers.
Biomarker Validation
Supporting the evaluation and validation of emerging biomarkers and their potential clinical applications.
Diagnosis
Supporting the detection of molecular biomarkers relevant to disease diagnosis.
Patient Stratification
Enabling molecular information that could help identify and differentiate patient groups.
Disease Monitoring
Creating opportunities to track molecular changes over time through minimally invasive sampling.
Our platform is being developed as a technology foundation for multiple diagnostic applications and biomarker development opportunities, rather than a single-disease solution.
Publicly supported development
XPOTDx is advancing its technology through publicly supported R&D programmes, non-dilutive funding and strategic collaborations. This support provides external validation while enabling the company to reach key technology and application milestones and progressively de-risk the platform ahead of its next stage of growth.
Non-Dilutive Funding
Supporting technology development and validation while reducing early-stage financing risk.
Strategic Collaborations
Working with complementary technology and research partners to accelerate platform development.
Collaborative R&D
Advancing the platform through publicly supported research and development programmes.
Together, these programmes and partnerships enable XPOTDx to build value and reduce technology risk before its next stage of financing and commercial development.
Why XPOTDx?
XPOTDx combines proprietary sensing technology, a growing portfolio of molecular detection applications and a platform strategy designed to address multiple clinical needs. Our approach is focused on building long-term value through technology development, validation and strategic partnerships.
Proprietary Technology
A differentiated sensing platform built around HFF-QCMD sensor arrays.
Platform Potential
Designed to extend across biomarker classes and multiple diagnostic applications.
Multiple Paths to Clinical Value
Opportunities spanning biomarker validation, diagnosis, patient stratification and disease monitoring.
De-Risked Development
Public funding, collaborative R&D and strategic partnerships supporting technology development and validation.
Let´s Talk
We are building relationships with investors, diagnostics companies, pharmaceutical companies and strategic partners who share our vision for the future of molecular diagnostics.
Whether you are interested in our technology, potential applications or the opportunity to partner with XPOTDx, we would be happy to start a conversation.
